January 2022 "Watch our CEO Tim Dyer on AlphaStreet. In his interview, Mr. Dyer provides an overview of our #allostericmodulator pipeline and the potential $4 billion market for our lead compound #dipraglurant in #PDLID (#Parkinsonsdisease levodopa-induced #dyskinesia)." Read more at the source #DrGPCR #GPCR #IndustryNews

April 2022 Addex Therapeutics Completes Patient Enrollment For Dipraglurant Blepharospasm Phase 2 Clinical Study " Geneva, Switzerland, April 13, 2022 - Addex Therapeutics Ltd (SIX: ADXN, Nasdaq: ADXN), a clinical-stage

August 2022 "Geneva, Switzerland, August 18, 2022 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage priorities, including pursuing additional collaborations across our portfolio,” said Tim Dyer , CEO of Addex

< GPCR News < GPCRs in Oncology and Immunology Noval insights and therapeutic strategies for tumor-induced receptor (TACR3), a homolog of the G protein-coupled receptor TkR99D in fruit flies, as a potential therapeutic The implications of these findings for transforming the therapeutic approaches to renal complications These insights could contribute to the advancement of diagnostic and therapeutic strategies for treating

< GPCR News < GPCRs in Oncology and Immunology CCR6 as a Potential Target for Therapeutic Antibodies This review highlights the potential as a therapeutic target of the CCR6 receptor in numerous diseases

Sponsors GPCR Retreat Program < Back to schedule Inhibition of Relaxin Autocrine Signaling Confers Therapeutic Several of these targets are being developed for potential new therapeutic strategies in ovarian and